醫學新知與專欄 第二型糖尿病新藥介紹: GLP-1 (類升糖素胜 肽 …

252 醫學新知與專欄 第二型糖尿病新藥介紹: GLP-1 (類升糖素胜 肽-1 glucagon -like peptide-1）在第二型 糖尿病治療的角色

常見老年症候群―跌倒 - doctor.org.tw

238 高雄醫師會誌 journal of kaohsiung medical association 2010. vol.18, no.3 程圖(圖2)，裡面提到所有第一線醫 療人員，尤其是醫師均應於看診時

醫學專欄 強心劑在心臟衰竭病患的使用

345 強心劑在心臟衰竭病患的使用 劑、血管升壓素轉換酶抑制劑、乙 型交感神經受體阻斷劑、血管升 壓素ii 接受器阻斷劑 ...

高雄醫師會誌 JOURNAL OF KAOHSIUNG MEDICAL …

29 水腦症 參考文獻 1. Bergsneider M, Miller C, Vespa PM, Hu X: Surgical management of adult hydrocephalus. Neurosurgery 62 [Suppl 2]:643-59,

  Hydrocephalus

Appendix I: Glucose Conversion Between mg/dl and mmol/L

318 Index Genetics, 15, 16 Gestational diabetes, 305 Glucagon, 43, 44, 47, 48 Glucagon-like peptide (GLP-1), 25 Glucagon (school), 253 Glucophage (metformin), 24

  Between, Appendix, Conversion, Glucagon, Peptides, Glucose, Like, Appendix i, Glucose conversion between mg dl, Like peptide

THE J BIOLOGICAL C - Glucagon.com

Glucagon-like Peptide-1 Receptor Signaling Modulates Cell Apoptosis* Received for publication, September 13, 2002, and in revised form, October 22, 2002

  Glucagon, Peptides, Like, Signaling, Receptors, Modulates, Like peptide 1 receptor signaling modulates

GLP-1 analogs and DPP-4 inhibitors - Denver, Colorado

Preliminary safety concerns with GLP-1 agents “Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1 based therapies”Elashoff M et al. Gastroenterology 2011;141: 150-6

  Analog, Glucagon, Peptides, Like, Inhibitors, Like peptide, 1 analogs and dpp 4 inhibitors

A new glucagon and GLP-1 co-agonist eliminates obesity in ...

gluconeogenesis and glycogenolysis, whereas GLP-1 acts by multiple mechanisms to lower glucose, most notably by enhancing glucose-stimulated insulin synthesis and secretion at the pancreas16.Another

  Obesity, Glucagon, Agonist, Eliminates, Insulin, 1 co agonist eliminates obesity

8. Pharmacologic Approaches to Glycemic Treatment ...

Educationregardingmatchingprandial insulin dosing to carbohydrate intake, premeal glucose levels, and anticipated activity should be considered, and se-

  Insulin

Inpatient Management of Hyperglycemia and Diabetes

CLINICAL DIABETES • Volume 29, Number 1, 2011 3 F E A T U R E A R T I C L E Inpatient Management of Hyperglycemia and Diabetes Vasudev Magaji, MD, MS, and Jann M. Johnston, MD

  Management, Inpatient, Inpatient management of hyperglycemia and, Hyperglycemia

Diabetes Mellitus - OPL

2 Recognize the role of pharmacists in diabetes care. Define diabetes mellitus (DM). Compare and contrast type 1 and 2 diabetes presentation, onset, progression, and pathophysiology. List the plasma glucose levels that diagnose a patient with: impaired fasting glucose, impaired glucose tolerance, or DM. Apply evidence -based recommendations to non-pharmacologic and pharmacologic treatment

  Diabetes, Diabetes mellitus, Mellitus

HIGHLIGHTS OF PRESCRIBING INFORMATION ...

1 ——— CONTRAINDICATIONS ——— VICTOZA® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4). VICTOZA® is contraindicated in patients with a prior serious hypersensitivity reaction to VICTOZA® or any of the product components (4).